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tion but might actually restore immune competence in
the HIV-infected person. This would undoubtedly be
enhanced by a better understanding of HIV-1 patho-
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measures to interrupt transmission. The chemokine re-
Introduction ceptor CCR5 is the principal coreceptor used by HIV-1
In the four decades that human immunodeficiency virus for entry into cells in primary infection. Although in vitro
type 1 (HIV-1) has afflicted the human population, the HIV-1 can use a variety of chemokine receptors to gain
virus has spread rapidly into most parts of the world, entry into cells, the virus shows a powerful (and poorly
leading to the death of over 16 million people. Infection understood) requirement for CCR5 usage in the early
with HIV-1 is characterized by a relentless decline in stages of human infection, making CCR5 an important
both numbers and function of CD41 T helper (Th) lym- therapeutic target.
phocytes, which play a central role in coordinating im- The first cells to become infected in vivo in the ma-
mune responses. Ultimately, the weakened immune sys- caque model include CD41 T cells (activated and rest-
tem loses control of viral replication and the syndrome ing) and dendritic cells (DC). There has been controversy
known as Acquired Immunodeficiency Syndrome (AIDS) about the role of DCs in HIV-1 pathogenesis. DCs pro-
develops. Despite intense study, many fundamental is- vide a sophisticated system for collecting and pro-
sues in HIV-1 pathogenesis remain poorly understood. cessing foreign antigens in the periphery and trans-
Not everyone exposed to the virus becomes persistently porting them to T cell–rich areas of lymphoid tissue,
infected and there is considerable heterogeneity in the where they initiate immune responses to their cargo of
clinical course of HIV infection, with some people pro- antigens. It seems likely that HIV-1 exploits these cells
gressing rapidly to disease and death while others show like a modern day Trojan horse, hitching a ride from the
mucosa into the heart of the lymphoid system, to anno signs of immunodeficiency for decades. Is this a
environment rich in susceptible activated CD41 T cells.reflection of the striking variability of the virus (see the
HIV-1 may not need to infect DCs in order to travel withaccompanying article by Mike Malim [this issue of Cell])
them. It was shown last year that an HIV binding DC-or a consequence of different host factors affecting
specific surface molecule, DC-SIGN (Geitjenbeek et al.,pathogenesis? Genetic influences on the outcome of
2000), can act as a high-affinity ligand for HIV-1 enve-HIV-1 infection are increasingly recognized, which can
lope, maintaining viable virus for several days. Thisindicate potential mechanisms in the pathogenesis of
would allow the virus to survive outside the cell until itHIV-1 infection. These studies are valuable because
reaches the lymph node. Key issues about DC-SIGNwhat actually causes the devastating immune deficiency
remain to be addressed, such as how its expressionof HIV-1 infection—out of proportion to the actual num-
is regulated and whether DC-SIGN polymorphism canber of HIV-infected Th cells—is not entirely clear, nor
affect individual HIV-1 susceptibility. We need to knoware we certain why the potent immune response against
more about the actual role of this molecule in vivo, butthe virus ultimately fails to contain viral replication. Most
it could be a potential therapeutic target for interruptinggenetic studies have focused on polymorphisms in host
HIV-1 transmission. Intriguingly, HIV-1 envelope pro-response genes or receptors used by the virus to gain
teins have the ability to attract DCs directly in vitro,entry into cells, but the wealth of new genetic informa-
through subversion of the CCR5 chemokine signalingtion anticipated with the recent publication of the Human
pathway (Lin et al., 2000), which could allow HIV-1 toGenome should provide pointers to unexpected genetic
take maximum advantage of the DC transport system.factors that contribute to HIV-1 pathogenesis.
Once HIV-1 infection is established, the most strikingDeveloping effective therapeutic strategies against a
feature of immune dysfunction is an early and progres-highly mutable virus that is integrated into the genome of
sive loss of CD41 T cell help, first to HIV-1 antigens anda crucially important population of immune cells poses a
then to other recall antigens. The loss of HIV-1-specificmajor challenge. Our most effective antiretroviral drugs
Th responses could be a direct consequence of DCsare limited in scope to interfering with active viral replica-
transporting virus to the lymph node, where activatedtion. Despite initial optimism about the potential of com-
T cells recruited to respond to viral antigens would bebination antiretroviral therapy ultimately to eradicate the
highly susceptible to infection. There is considerablevirus, few clinicians now expect to lengthen the life of
debate about what happens to the general pool of T
their patients more than a few years before drug side
cells in the infected person, initially reported to undergo
effects and viral resistance undermine the benefits of
a highly dynamic process of CD41 T cell production
therapy. Increasing attention is being given to devel- and destruction. Human T cell turnover is a difficult area
oping regimens that do not simply control viral replica- to study but a consensus is emerging. The key feature
appears to be a modest but significant shortening of
CD41 T cell survival not matched by a corresponding* To whom correspondence should be addressed (e-mail: sarah.
rowland-jones@ndm.ox.ac.uk). increase in the supply of new T cells (Hellerstein et al.,
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et al., 2000); escape variants also accumulate in HIV-1-
infected humans. Recent attention has focused on the
quality of the HIV-specific CTL response, following ob-
servations that LCMV-infected mice deficient in T cell
help generated virus-specific CTL that neither killed nor
produced antiviral factors. Since most HIV-1-infected
people lack Th responses to the virus, CTL function
could be similarly impaired. HIV-specific CTL produce
a full range of antiviral cytokines and chemokines on
encounter with antigen, but are characterized by low
levels of perforin, a key mediator of cytolysis. This is
associated with less efficient target cell killing and a
pattern of cell-surface markers previously thought to
indicate immature T cells (Appay et al., 2000). The resto-
ration of HIV-specific immune responses, particularly Th
Figure 1. HIV-1 Associated Factors responses, has become a major goal of HIV therapy.
The figure shows factors associated with HIV-1 susceptibility and Host Genetics and the Natural History
rapid disease progression (left) or with HIV-1 resistance and slow of HIV-1 Infection
progression. Compelling evidence that host genetics play a role in
HIV-1 susceptibility and disease progression (Figure 1)
have come from epidemiological studies focusing on1999). Naı¨ve T cell production depends on several fac-
individuals who remain uninfected despite HIV-1 expo-tors, including progenitor cell capacity, thymic function,
sure, and people with unusually slow disease progres-and peripheral division (Hazenberg et al., 2000), all of
sion. Long-term nonprogressors (LTNPs), with a normalwhich may be affected by HIV-1 infection. However,
CD41 count and undetectable viral load more than 10CD81 T cell survival is not significantly reduced by HIV-1
years after infection, account for less than 5% of HIV-infection, and production is modestly increased (Heller-
1-infected people. LTNPs are frequently distinguishedstein et al., 1999), so it is important to consider these T
by preservation of proliferative Th responses to HIV anti-cell subsets separately. Future studies would benefit
gens, in contrast to the majority of infected people. Itfrom a precise definition of memory and naı¨ve T cells
is worth pointing out that the majority of genetic studieswith a sophisticated panel of T cell markers to clarify
to date have focused on Western cohorts, and do notthe fate of these different populations.
necessarily shed any light on factors influencing clinicalThe Immune Response to HIV-1
outcome in the majority of the world’s HIV-1-infectedThe major issue hindering progress toward an effective
population, in Africa and Asia.vaccine to prevent or modulate HIV-1 infection is that
Several chemokine receptor polymorphisms are knownthe critical features needed for a protective immune
to influence the outcome of infection (reviewed in
response are not fully understood. Although potent neu-
O’Brien and Moore, 2000). The most well-characterized
tralizing antibodies can protect against experimentally
is a deletion in the CCR5 gene (CCR5D32), leading to
acquired infection in animal models, they are rarely gener-
absent CCR5 expression on the cell surface in homozy-
ated in vivo in the infected person, and neutralization- gotes (who account for about 1% of Caucasians but
resistant viral variants develop rapidly in chronic infection. much less in other racial groups). Homozygotes are re-
It is generally agreed that cellular immune responses, sistant to infection with R5 virus strains and heterozy-
particularly specific cytotoxic T lymphocytes (CTL), are gotes show slower disease progression. A number of
important in the host response to HIV-1. This was shown other polymorphisms in the CCR5 promoter region have
by a rapid upsurge in viral replication in macaques de- been linked with the rate of HIV-1 disease progression,
pleted of CD81 T cells, in both acute (Schmitz et al., but the impact of most of these variants on CCR5 ex-
1999) and chronic SIV infection. CTL develop very early pression and function is not known. A point mutation
in acute HIV-1 infection, coincident with a rapid fall in that leads to a conservative substitution in one of the
plasma viremia, and in chronic infection, their levels are transmembrane regions of the CCR2b receptor has been
inversely related to viral load. Their weapons against shown to be linked with delayed disease progression in
HIV-1 include the ability to kill infected cells before new both Caucasian and African cohorts, somewhat surpris-
virus progeny are produced and to secrete potent antivi- ingly since the receptor is only rarely used by HIV-1.
ral factors, including chemokines that compete with In late disease, the virus population in many people
HIV-1 for the CCR5 receptor. These properties are not evolves to use a second coreceptor, CXCR4. This is the
unique to CTL, but the ability to recognize infected T ligand for the chemokine Stromal-derived Factor (SDF-1),
cells through the presentation of viral peptides in class produced by endothelial cells and associated with wide-
I HLA molecules allows CTL to home in on sites of active ranging effects on lymphocytes. Studies in knockout
viral replication. mice show that CXCR4 plays a critical role in a number
However, the powerful HIV-specific CTL response ulti- of processes, including hematopoiesis, cerebellar de-
mately fails to control HIV replication. One reason could velopment, and vascularization of the gastrointestinal
be the emergence of viral variants that escape CTL rec- tract, so both CXCR4 and SDF-1 are crucial to survival
ognition. Viral variants with CTL escape mutations in and show little genetic variability. A single polymorphism
the SIV tat gene were detected at high frequency in has been described in the 39 untranslated region of the
SDF-1 gene, although its effect on SDF-1 function is notmacaques shortly after infection with cloned SIV (Allen
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Table 1. Impact of the Timing of Antiretroviral Therapy on Viral Parameters and Components of the Host HIV-Specific Cellular Immune
Response
Early therapy* 6 STI† Late therapy‡
Plasma viremia ### ###
CD4 count/mm3 " ""
Anti-HIV CTL activity early ", gradual # gradual #
Anti-HIV T-helper activity "" generally not detected
Anti-HIV CD81 noncytotoxic activity #/" "
Cumulative in vivo HIV replication low very high
HIV viral diversity low high
* Antiretroviral therapy initiated within 6 months of primary infection.
† Supervised treatment interruption.
‡ Antiretroviral therapy more than 6 months after primary infection.
known. Studies of this polymorphism in relation to HIV-1 with a cluster of related class I alleles (HLA-A2/A*6802)
and with HLA-DR1, while increased susceptibility wasdisease progression have led to conflicting results, but
intriguingly, the rare allele was recently linked with in- strongly linked with HLA-A23 (MacDonald et al., 2000).
Although the mechanisms underlying HLA associa-creased likelihood of HIV-1 transmission from mother
to child (John et al., 2000), the first report of a genetic tions with the outcome of HIV-1 infection are not fully
understood, the implication of these studies is that thefactor associated with increased HIV-1 infectivity.
Recent attention has focused on polymorphisms in efficiency of the host response to HIV varies according
to HLA type. Maximum HLA heterozygosity allows thethe gene coding for the chemokine RANTES, one of the
ligands for CCR5 produced by CD81 T cells. RANTES greatest potential repertoire of HIV-1 peptides to be
presented to CTL, and the HIV-1 epitopes associatedhas pleomorphic effects, both on T cell activation and
on HIV-1 replication, leading to HIV-1 suppression in T with “beneficial” class I molecules may induce a particu-
larly effective immune response. It is harder to explaincell cultures but amplifying viral replication at higher
concentrations, particularly in macrophage cultures. A the adverse effects of certain HLA types on clinical out-
come. It is possible that a dominant but ineffective re-compound genotype involving two single nucleotide
polymorphisms (SNPs) in the upstream coding region sponse through a less favorable HLA molecule could
divert the immune system away from more efficient anti-of the RANTES gene has been associated with increased
RANTES transcription and delayed disease progression viral responses, but there is no evidence yet to support
this concept.in cohorts of HIV-1-infected individuals in Japan and
the USA (Liu et al., 1999; McDermott et al., 2000). Para- Cytokine gene polymorphisms also play a part in the
outcome of HIV-1 infection. It was recently reporteddoxically, the American study showed that this haplo-
type also acts as a risk factor for HIV-1 infection, almost that HIV-1-infected individuals with a particular IL-10
promoter haplotype had increased risk of HIV-1 infectiondoubling the likelihood of infection (McDermott et al.,
2000). The authors speculate that increased RANTES and progression to AIDS (Shin et al., 2000), particularly
in late stages of infection. This IL10-59A promoter poly-production may facilitate HIV entry by promoting inflam-
mation at mucosal surfaces, but once infection takes morphism alters binding of nuclear transcription factors
and is thought to downregulate production of this Th2-place, competition between RANTES and the virus for
CCR5 hinders virus spread. These studies should stimu- type cytokine. The study is consistent with a protective
role for IL-10 in the natural history of HIV-1 infectionlate work to define more precisely the impact of RANTES
production on HIV-1 replication, and its potential use in (despite previous controversy in this area) and should
stimulate further research on the part played by IL-10HIV-1 therapy.
Another well-documented influence on the natural his- in HIV pathogenesis.
HIV Therapy: Past, Present, and Futuretory of HIV-1 infection is the major histocompatibility
complex (MHC), our most polymorphic set of genes. Although AIDS-related morbidity and mortality were dra-
matically reduced by combination antiretroviral therapyAmino acid substitutions are concentrated in the pep-
tide binding groove of HLA molecules and will therefore (Lederman and Valdez, 2000), current therapeutic strate-
gies have limitations. Cumbersome regimens and ainfluence the nature of epitope peptides that bind and
are presented to T cells. Slow disease progression is linked plethora of drug side effects lead to poor compliance,
and viruses bearing drug resistance mutations now ac-with several class I HLA molecules, notably HLA-B27 and
B57. Recently, Carrington et al. (1999) reinforced the im- count for a significant number of new infections. Early
optimism that antiretroviral therapy could eradicate HIV-1portance of MHC heterozygosity as a selective advantage
in viral infection by showing that maximum HLA hetero- was tempered on observing the rapid viral relapse that
occurs when therapy is discontinued. In consideration ofzygosity at the A, B, and C class I loci delayed the onset
of AIDS. This study also demonstrated an association these factors, an argument has been made for delaying
therapy in asymptomatic, HIV-infected individuals withbetween the HLA-B35-Cw*04 haplotype and rapid dis-
ease progression in Caucasians. Fewer studies have adequate CD41 T cell counts. In this approach, treat-
ment for these patients would be reserved until later inexamined HLA associations with resistance or suscepti-
bility to HIV-1 infection. In a cohort of African sex work- the disease, when the benefits are likely to outweigh
the problems of side-effects and viral resistance.ers, a reduced risk of HIV-1 infection was associated
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There is debate as to whether antiretroviral therapy ment or fusion. Several promising compounds have
helps or harms the immune system in its battle with the been identified (reviewed in D’Souza et al., 2000) and
virus. Suppression of plasma viremia in chronic infection clinical trials are now underway, although it is likely to
is usually associated with loss or reduction of HIV-1- be some time before this will translate into a new class
specific CTL responses (Altfeld et al., 2001) (see Table of antiretroviral drugs.
1), which could reduce the ability of the immune system
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The future generation of HIV therapies consists largely
of agents aiming to inhibit the critical early interactions
between the virus and its target cell, either acting at the
level of CD4 or the chemokine receptor or targeting
envelope glycoproteins, with a view to blocking attach-
